SEER*Explorer Application
SEER*Explorer provides access to SEER cancer statistics and detailed statistics for a cancer site by gender, race, calendar year, age, and for a selected number of cancer sites, by stage and histology.
SEER*Explorer provides access to SEER cancer statistics and detailed statistics for a cancer site by gender, race, calendar year, age, and for a selected number of cancer sites, by stage and histology.
New research findings have highlighted the importance of personalized treatment approaches with the monoclonal antibody durvalumab based on mismatch repair (MMR) status in newly diagnosed…
An abstract is unavailable.
Kian-Huat Lim, MD, PhD, discusses the role of multidisciplinary collaboration and clinical trials in the treatment of pancreatic cancer.
Transfusion of red blood cells (RBCs) can be lifesaving for individuals living with sickle cell disease (SCD). However, alloimmunization following transfus
About Oncology Prescription Drug Labeling
Key Points. Previous studies showed that fludarabine PK exposure is associated with key outcomes in pediatric patients after tisagenlecleucel.In adults receivin
Currently, many off-the-shelf chimeric antigen receptor (CAR)-T cell products are under investigation for the treatment of relapsed or refractory (R/R) B-cell neoplasms. Compared with autologous…
CAR T cells display distinctive profiles and actions in patients with CNS autoimmunity.
Karim Chamie, MD, discusses the significance of the FDA approval of N-803 plus BCG in BCG-unresponsive non–muscle invasive bladder cancer.
Tina Cascone, MD, PhD, discusses who was included in the phase 3 CheckMate-77T trial and the key end points of the study.